Leflunomide, a disease‐modifying anti‐rheumatic drug, has been associated with elevations of serum aminotransferases. Herein, we describe the clinical, laboratory features and outcomes of 17 patients with leflunomide/teriflunomide hepatotoxicity from two… Click to show full abstract
Leflunomide, a disease‐modifying anti‐rheumatic drug, has been associated with elevations of serum aminotransferases. Herein, we describe the clinical, laboratory features and outcomes of 17 patients with leflunomide/teriflunomide hepatotoxicity from two large drug‐induced liver injury (DILI) registries.
               
Click one of the above tabs to view related content.